← Leaderboards
Irvin S.y. Chen
University Of California Los Angeles
$31,294,828
Attributed
$32,005,569
Total exposure
25
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$69,543,225 · 28
By mechanism
U19$29,299,607 · 10
P30$19,918,922 · 3
R01$18,380,932 · 10
R21$984,265 · 3
T32$578,503 · 1
R56$380,996 · 1
Top collaborators
- Scott G Kitchen10 shared
- Tom Chou1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Dong Sung An$9,622,627
- Masakazu Kamata$5,573,549
- Scott G Kitchen$17,099,191
- Harold George Monbouquette$4,165,441
- Jing Wen$2,923,926
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGene TherapyHiv-1ProgramsVectorT-LymphocyteInfectionTissuesClinical ResearchLentivirus VectorMouse ModelNonhuman PrimateIn VivoMacaca MulattaCcr5 GeneGenesHematopoietic Stem CellsHiv InfectionsGrantBaseHematopoieticGenetic EngineeringGene-ModifiedLife
Grant awards (107)
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,848,211
U19 · FY2024 · AI
Core-002$490,362
U19 · FY2024 · AI
Core-001$276,585
U19 · FY2024 · AI
Project-002$158,034
U19 · FY2024 · AI
Admin-Core-001$75,492
U19 · FY2024 · AI
Project-003$40,013
U19 · FY2024 · AI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,848,126
U19 · FY2023 · AI
In Vivo Gene Editing for HIV-1 Cure$678,009
R01 · FY2023 · AI · contact PI
Administrative Core$187,401
U19 · FY2023 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,847,671
U19 · FY2022 · AI
In Vivo Gene Editing for HIV-1 Cure$678,009
R01 · FY2022 · AI · contact PI
Administrative Core$200,531
U19 · FY2022 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,847,927
U19 · FY2021 · AI
In Vivo Gene Editing for HIV-1 Cure$678,009
R01 · FY2021 · AI · contact PI
Administrative Core$194,442
U19 · FY2021 · AI · contact PI
(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV$2,872,207
U19 · FY2020 · AI
In Vivo Gene Editing for HIV-1 Cure$678,009
R01 · FY2020 · AI · contact PI
Administrative Core$195,000
U19 · FY2020 · AI · contact PI
Anti-HIV Gene Therapy: Defend and Attack$1,929,696
U19 · FY2019 · AI · contact PI
In Vivo Gene Editing for HIV-1 Cure$678,009
R01 · FY2019 · AI · contact PI
Tracking the clonal behavior of repopulating cells$382,763
U19 · FY2019 · AI · contact PI
Administrative Core$138,101
U19 · FY2019 · AI · contact PI
Anti-HIV Gene Therapy: Defend and Attack$1,956,462
U19 · FY2018 · AI · contact PI
Hematopoietic stem/progenitor cell reservoirs$385,000
R01 · FY2018 · AI · contact PI
Tracking the clonal behavior of repopulating cells$289,472
U19 · FY2018 · AI · contact PI
Administrative Core$140,047
U19 · FY2018 · AI · contact PI
Developmental Core$133,540
P30 · FY2018 · AI · contact PI
Anti-HIV Gene Therapy: Defend and Attack$2,135,528
U19 · FY2017 · AI · contact PI
Developmental Core$724,476
P30 · FY2017 · AI · contact PI
Tracking the clonal behavior of repopulating cells$488,723
U19 · FY2017 · AI · contact PI
Hematopoietic stem/progenitor cell reservoirs$385,000
R01 · FY2017 · AI · contact PI
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification$385,000
R01 · FY2017 · HL · contact PI
Administrative Core$136,582
U19 · FY2017 · AI · contact PI
Anti-HIV Gene Therapy: Defend and Attack$2,344,519
U19 · FY2016 · AI · contact PI
Developmental Core$747,577
P30 · FY2016 · AI · contact PI
Hematopoietic stem/progenitor cell reservoirs$385,000
R01 · FY2016 · AI · contact PI
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification$385,000
R01 · FY2016 · HL · contact PI
Tracking the clonal behavior of repopulating cells$339,442
U19 · FY2016 · AI · contact PI
Administrative Core$134,775
U19 · FY2016 · AI · contact PI
Anti-HIV Gene Therapy: Defend and Attack$2,256,106
U19 · FY2015 · AI · contact PI
Developmental Core$729,266
P30 · FY2015 · AI · contact PI
Tracking the clonal behavior of repopulating cells$405,545
U19 · FY2015 · AI · contact PI
Hematopoietic stem/progenitor cell reservoirs$385,000
R01 · FY2015 · AI · contact PI
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification$385,000
R01 · FY2015 · HL · contact PI
Gene engineering using CRISPR/Cas9 mutagenesis to eliminate latent HIV-1$192,500
R21 · FY2015 · AI · contact PI
Administrative Core$139,844
U19 · FY2015 · AI · contact PI
Developmental Core$1,060,893
P30 · FY2014 · AI · contact PI
Hematopoietic stem/progenitor cell reservoirs$385,000
R01 · FY2014 · AI · contact PI
Survival of the fittest HSPC repopulating clones by anti-HIV-1 gene-modification$385,000
R01 · FY2014 · HL · contact PI
Mouse and mathematical models for HIV-1 suppression through HSPC$380,996
R56 · FY2014 · HL · contact PI
Gene engineering using CRISPR/Cas9 mutagenesis to eliminate latent HIV-1$231,000
R21 · FY2014 · AI · contact PI
Developmental Core$979,722
P30 · FY2013 · AI · contact PI
Developmental Core$831,180
P30 · FY2012 · AI · contact PI
Developmental Core$840,841
P30 · FY2011 · AI · contact PI
Developmental Core$434,690
P30 · FY2010 · AI · contact PI
Modeling HIV-1 SiRNA Therapy$385,000
R01 · FY2010 · AI · contact PI
Retargeting of Retroviral Vectors$337,610
R01 · FY2010 · AI · contact PI
Developmental Core$409,123
P30 · FY2009 · AI · contact PI
Modeling HIV-1 SiRNA Therapy$385,000
R01 · FY2009 · AI · contact PI
Retargeting of Retroviral Vectors$341,020
R01 · FY2009 · AI · contact PI
Molecular Imaging of Cancer In vivo via Targeted Transduction$234,840
R01 · FY2009 · CA · contact PI
Developmental Core$376,411
P30 · FY2008 · AI · contact PI
Retargeting of Retroviral Vectors$341,020
R01 · FY2008 · AI · contact PI
Molecular Imaging of Cancer In vivo via Targeted Transduction$234,840
R01 · FY2008 · CA · contact PI
Targeting Gene Delivery to the CNS Blood-Brain Barrier$202,781
R21 · FY2008 · NS · contact PI
UCLA Center for AIDS Research (CFAR)$1,777,256
P30 · FY2007 · AI · contact PI
Retargeting of Retroviral Vectors$347,625
R01 · FY2007 · AI · contact PI
HIV-1 Vpr Induces G2 Cell Cycle Arrest and Apoptosis$309,836
R01 · FY2007 · CA · contact PI
Modeling HIV-1 siRNA Therapy$289,195
R01 · FY2007 · AI · contact PI
Molecular Imaging of Cancer In vivo via Targeted Transduction$234,840
R01 · FY2007 · CA · contact PI
Targeting Gene Delivery to the CNS Blood-Brain Barrier$168,984
R21 · FY2007 · NS · contact PI
UCLA Center for AIDS Research (CFAR)$1,764,129
P30 · FY2006 · AI · contact PI
Retargeting of Retroviral Vectors$347,625
R01 · FY2006 · AI · contact PI
HIV-1 Vpr Induces G2 Cell Cycle Arrest and Apoptosis$319,089
R01 · FY2006 · CA · contact PI
Modeling HIV-1 siRNA Therapy$297,833
R01 · FY2006 · AI · contact PI
Interdisciplinary Training in Virology and Gene Therapy$211,985
T32 · FY2006 · AI · contact PI
UCLA Center for AIDS Research (CFAR)$1,735,847
P30 · FY2005 · AI
Structure/Function of HIV-1 Vpr Associated Cell Proteins$463,880
R01 · FY2005 · AI
HIV-1 Vpr Induces G2 Cell Cycle Arrest and Apoptosis$326,768
R01 · FY2005 · CA
Modeling HIV-1 siRNA Therapy$305,000
R01 · FY2005 · AI
PRIMATE LENTIVIRUS BASED THERAPY VECTORS$305,000
R01 · FY2005 · AI
Interdisciplinary Training in Virology and Gene Therapy$210,219
T32 · FY2005 · AI
UCLA Center for AIDS Research (CFAR)$1,691,762
P30 · FY2004 · AI
Structure/Function of HIV-1 Vpr Associated Cell Proteins$450,441
R01 · FY2004 · AI
HIV-1 Vpr Induces G2 Cell Cycle Arrest and Apoptosis$324,653
R01 · FY2004 · CA
Modeling HIV-1 siRNA Therapy$305,000
R01 · FY2004 · AI
PRIMATE LENTIVIRUS BASED THERAPY VECTORS$305,000
R01 · FY2004 · AI
Interdisciplinary Training in Virology and Gene Therapy$156,299
T32 · FY2004 · AI
UCLA Center for AIDS Research (CFAR)$842,284
P30 · FY2003 · AI
Structure/Function of HIV-1 Vpr Associated Cell Proteins$437,395
R01 · FY2003 · AI
HIV-1 Vpr Induces G2 Cell Cycle Arrest and Apoptosis$322,538
R01 · FY2003 · CA
PRIMATE LENTIVIRUS BASED THERAPY VECTORS$305,000
R01 · FY2003 · AI
Modeling HIV-1 siRNA Therapy$305,000
R01 · FY2003 · AI
UCLA CENTER FOR AIDS RESEARCH (CFAR)$1,634,023
P30 · FY2002 · AI
Structure/Function of HIV-1 Vpr Associated Cell Proteins$370,588
R01 · FY2002 · AI
PRIMATE LENTIVIRUS BASED THERAPY VECTORS$305,584
R01 · FY2002 · AI
HIV 1 VPR INDUCES G2 CELL CYCLE ARREST AND APOPTOSIS$299,709
R01 · FY2002 · CA
UCLA CENTER FOR AIDS RESEARCH (CFAR)$1,512,031
P30 · FY2001 · AI
Structure/Function of HIV-1 Vpr Associated Cell Proteins$388,422
R01 · FY2001 · AI
PRIMATE LENTIVIRUS BASED THERAPY VECTORS$306,000
R01 · FY2001 · AI
HIV 1 VPR INDUCES G2 CELL CYCLE ARREST AND APOPTOSIS$291,650
R01 · FY2001 · CA
UCLA CENTER FOR AIDS RESEARCH (CFAR)$227,237
P30 · FY2001 · AI
UCLA CENTER FOR AIDS RESEARCH (CFAR)$1,466,634
P30 · FY2000 · AI
STRUCTURE/FUNCTION OF HIV1 VPR ASSOCIATED CELL PROTEINS$432,828
R01 · FY2000 · AI
MODELLING GENE THERAPEUTICS APPROACHES IN SCID-HU MICE$309,185
R01 · FY2000 · DK
HIV 1 VPR INDUCES G2 CELL CYCLE ARREST AND APOPTOSIS$260,873
R01 · FY2000 · CA
A RATIONAL APPROACH TO DEVELOPING A KILLED HIV-1 VACCINE$189,000
R21 · FY2000 · AI